Skip navigation

Emerging Trends, Best Practices and Benchmarking for Managing Risks Associated with Complex, High-Touch Therapies

September 22-23, 2020
  • Boston, MA

CBI’s 6th Annual Compliance Congress for Specialty Products is the life sciences industry’s only conference catered to the unique compliance challenges for specialty pharmaceutical companies, pre- and post-commercialization.

While specialty products are immensely valuable to patients, they also bring unprecedented risks for pharmaceutical companies. A comprehensive compliance program is essential to correctly assessing risks, including patient support services, non-promotional activities, third-party relationships and pharmacy contracting. At this highly-acclaimed annual meeting, take the opportunity to identify and address the top risk areas for specialty product manufacturers and compare strategies for promoting a compliant culture within your organization.

Join the Compliance Community for Compelling Discussions On:

  • Risks Associated with Patient Support Services
  • Transforming the Internal Role of the Compliance Officer
    from Policeman to Partner
  • Third-Party Risk Management
  • Considerations for Cell and Gene Therapies
  • Boundaries for Medical and Commercial Activities
  • Transparent Relationships with Patient Advocacy Groups
    and Charitable Foundations
  • Nurses Educator Programs
  • And more!

PLUS! The Compliance Congress for Specialty Products will be collocated with the 16th Annual MedDevice and MedTech Compliance Congress. Visit cbinet.com/medtech for more information.

PREVIOUS ATTENDEE ACCLAIM:

Great information for someone starting out
in specialty pharma.

Associate Director, Compliance, PTC Therapeutics

This is the only conference that focuses on compliance for specialty products. The unique forum provides a great opportunity to share best practices and benchmark programs.

Chief Compliance Officer, Haemonetics

The speaking faculty scope and depth provided an outstanding view of specialty compliance risks
and tools to minimization.

Director, Govt Programs & Commercial Compliance, Prometric Biotherapeutics

6th Annual Compliance Congress for Specialty Products

Emerging Trends, Best Practices and Benchmarking for Managing Risks Associated with Complex, High-Touch Therapies

CBI’s 6th Annual Compliance Congress for Specialty Products is the life sciences industry’s only conference catered to the unique compliance challenges for specialty pharmaceutical companies, pre- and post-commercialization.

While specialty products are immensely valuable to patients, they also bring unprecedented risks for pharmaceutical companies. A comprehensive compliance program is essential to correctly assessing risks, including patient support services, non-promotional activities, third-party relationships and pharmacy contracting. At this highly-acclaimed annual meeting, take the opportunity to identify and address the top risk areas for specialty product manufacturers and compare strategies for promoting a compliant culture within your organization.

Join the Compliance Community for Compelling Discussions On:

  • Risks Associated with Patient Support Services
  • Transforming the Internal Role of the Compliance Officer
    from Policeman to Partner
  • Third-Party Risk Management
  • Considerations for Cell and Gene Therapies
  • Boundaries for Medical and Commercial Activities
  • Transparent Relationships with Patient Advocacy Groups
    and Charitable Foundations
  • Nurses Educator Programs
  • And more!

PLUS! The Compliance Congress for Specialty Products will be collocated with the 16th Annual MedDevice and MedTech Compliance Congress. Visit cbinet.com/medtech for more information.

PREVIOUS ATTENDEE ACCLAIM:

Great information for someone starting out
in specialty pharma.

Associate Director, Compliance, PTC Therapeutics

This is the only conference that focuses on compliance for specialty products. The unique forum provides a great opportunity to share best practices and benchmark programs.

Chief Compliance Officer, Haemonetics

The speaking faculty scope and depth provided an outstanding view of specialty compliance risks
and tools to minimization.

Director, Govt Programs & Commercial Compliance, Prometric Biotherapeutics